H.C. Wainwright reiterates Madrigal Pharmaceuticals stock rating citing market position
H.C. Wainwright reiterated a Buy rating and $620 price target for Madrigal Pharmaceuticals (MDGL), citing its market position and undervaluation. The company reported strong Q3 2026 results, including $431.3M revenue and $1.83 EPS, exceeding expectations. MDGL's gross profit margin is 90.96%, with 93% revenue growth over the last year.
How this was made
The 30-second read
Why it matters
Limited impact; the reiteration reinforces existing sentiment but adds no fresh catalyst.
Market read
The piece is a recap of prior earnings and analyst opinion, offering little new trading insight.
What to watch
No new clinical data or earnings surprise accompanies the rating.
Background
The article repeats an analyst's prior Buy rating and price target for MDGL, citing past earnings that were released nine days earlier.
Ticker impact
H.C. Wainwright reiterated a Buy rating and raised the price target to $620 for Madrigal Pharmaceuticals.
potential upward pressure as investors price in the higher target.
The rating change is a repeat of a prior view and does not introduce new fundamentals; impact is limited to sentiment.
Market effects
Minimal; the MASH therapy market remains unchanged.
None
Low
Counterpoint
The reiteration may be seen as overoptimistic given the modest recent price movement.
Key entities
- CompanyMadrigal Pharmaceuticals
Biopharma focused on MASH therapy.
- Research FirmH.C. Wainwright
Equity research provider issuing the rating.
